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Abstract: The close association between pre-existing Hashimoto’s thyroiditis and thyroid cancer is
well established. The simultaneous occurrence of multiple neoplastic foci within the same organ
suggests a common genotoxic effect potentially contributing to carcinogenesis, the nature of which
is still not clear. Next-generation sequencing (NGS) provides a potent tool to demonstrate and
compare the mutational profile of the independent neoplastic foci. Our collection of 47 cases with
thyroid carcinoma and Hashimoto’s thyroiditis included 14 with at least two tumorous foci. Detailed
histological analysis highlighted differences in histomorphology, immunoprofile, and biological
characteristics. Further, a 67-gene NGS panel was applied to demonstrate the mutational diversity of
the synchronic tumors. Significant differences could be detected with a wide spectrum of pathogenic
gene variants involved (ranging between 5 and 18, cutoff >5.0 variant allele frequencies (VAF)).
Identical gene variants represented in both synchronous tumors of the same thyroid gland were found
in only two cases (BRAF and JAK3 genes). An additional set of major driver mutations was identified
at variable allele frequencies in a highly individual setup suggesting a clear clonal independence.
The different BRAF statuses in coincident thyroid carcinoma foci within the same organ outline a
special challenge for molecular follow-up and therapeutic decision-making.
Keywords: autoimmune thyroiditis; mutational profiling; papillary thyroid carcinoma; mutagenesis;
next-generation sequencing (NGS); variant allele frequencies (VAF)
1. Introduction
Thyroid carcinoma is the most frequent endocrine neoplasia, the incidence of which is increasing
worldwide [1,2]. Major etiological factors include environmental and direct thyrotoxic effects, and
selected comorbidities such as autoimmune thyroid disease are also considered as associated factors [3,4].
While the immunological background and pathological consequences of autoimmune lymphocytic
thyroiditis and, more recently, IgG4-related chronic inflammation have been gradually elucidated,
the exact mechanisms of subsequent carcinogenesis are mostly unknown. Hashimoto’s thyroiditis
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(HT) is one of the most frequent autoimmune thyroid disorders characterized by massive lymphocytic
infiltrate and progressive destruction of the thyroid parenchyma [5,6]. The autoimmune attack results
in direct cellular toxicity, and regeneration is associated with endocrine and metabolic/oxidative stress
at the level of the thyroid follicular epithelium [7,8]. Parenchymal hypofunction, on the other hand,
triggers a constant proliferative stimulus by thyroid-stimulating hormone (TSH), enabling increased
survival and adaptive selection, which are both important factors in the process of carcinogenesis.
According to the current view, not only has the association between HT and especially papillary-type
thyroid carcinoma (PTC) been established, but the frequent multifocality of PTC can also be explained
by HT-related injury and consequent stimulatory mechanisms [6,9].
With the recent developments of genomic DNA testing, a sharpened picture of relevant gene
alterations and molecular pathways can also be provided for thyroid malignancies. The availability
of next-generation sequencing (NGS) approaches enables the large-scale analysis of cancer genotype
from archived pathological material [10,11]. Several well-documented studies using NGS were
performed to define the mutational spectrum of thyroid carcinoma, especially focusing on advanced
and anaplastic carcinoma cohorts [12,13]. Data obtained by extended cancer-related gene panel
analysis delineated MAPK and PI3K pathway mutations as contributing to aggressive behavior.
Following clinical interpretation of sequencing results, a path was cleared for targeted therapeutic
suggestions [14–16]. On the other hand, there is only limited information regarding the origin and
genetic background of thyroid cancer (TC) associated with HT. Interestingly, BRAF V600 mutations
were under-represented in association with HT-related PTC; however, other characteristic changes or
frequent gene variant patterns could not be identified [9]. Findings on multiple neoplastic nodules and
their clonal relation in the context of HT have also not been reported in the literature so far. Therefore,
following the histopathological evaluation of multifocal thyroid lesions provided in our single-center
cohort, we performed an NGS-based 67 multigene analysis in a selected set of HT-related TC cases
to highlight the mutational pattern and potential common features of this special and complex form
of carcinogenesis.
2. Materials and Methods
2.1. Tissue Samples and Histological Workup
Histological sections and clinicopathological data were used of TC patients operated on at the
Department of Surgery, University of Debrecen between 2007 and 2015 and diagnosed with the
parallel occurrence of TC and HT. Ethical aspects were covered by the approval of the Hungarian
National Health Science Committee (reg. no. 60355-2/2016/EKU). Histological slides were rescreened
for tumor multifocality and presence of lymphocytic infiltrate. HT was suggested if massive chronic
lymphocytic infiltration, secondary lymphatic follicles, and atrophy of the thyroid follicular epithelium
were obvious. The clinical history together with radiological and serological findings further supported
the autoimmune background and the diagnosis of HT in these cases. TC was confirmed by classical
histological criteria (cyto- and nuclear morphology, including nuclear clearing, irregularity, grooving,
and pseudoinclusions, as well as psammoma bodies) in hematoxylin-eosin-stained conventional
sections. Multifocality of TC was stated when more than one completely separate tumor cluster
was found at a distance of larger than 5 mm during the review of the surgical resection material.
Immunohistochemistry (IHC) for tissue antigens HBME1, galectin-3, CD56, and CK19 was applied to
clearly demonstrate the extent of thyroid cancer within individual tumor foci. IHC was done according
to our routine diagnostic protocols in a Ventana Ultra stainer (Roche Diagnostics Mannheim, Germany).
In addition, mutant BRAF status (clone VE1), the p53 status (clone DO-7), and the cell proliferation
rate (clone Mib-1) was also determined. Individual TC foci were compared for IHC characteristics by
conventional light microscopy by two experienced pathologists (C.M. and G.M.).
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2.2. DNA Isolation
DNA from the individual TC foci was removed and processed from the formaldehyde fixed
paraffin embedded (FFPE) sections following accurate dissection of the tumor area using a standard
protocol. Genomic DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany). DNA concentration was measured with the Qubit dsDNA HS Assay Kit in a Qubit 4.0
fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).
2.3. BRAF Mutation Testing
BRAF testing focusing on the clinically relevant tyrosine kinase domain mutation status was
independently performed in a routine session using conventional Sanger sequencing based on Big Dye
chemistry (Applied Biosystems, Foster City, CA, USA) in an ABI 310 genetic analyzer.
2.4. Library Preparation for NGS
The amount of amplifiable DNA (ng) was calculated according to the Archer PreSeq DNA
Calculator Assay Protocol (Archer DX, Boulder, CO, USA). After fragmentation of the genomic DNA,
libraries were created by the Archer VariantPlex Solid Tumor Kit (Archer DX, Boulder, CO, USA).
The solid tumor panel included the following 67 genes: ABL1, AKT1, ALK, APC, ATM, AURKA, BRAF,
CCND1, CCNE1, CDH1, CDK4, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4,
ESR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, H3F3A, HNF1A,
HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MDM2, MET, MYC, MYCN, MLH1, MPL,
NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTEN, PTPN11, RB1, RET, RHOA, ROS1, SMAD4,
SMARCB1, SMO, SRC, STK11, TERT, TP53, and VHL. The KAPA Universal Library Quantification Kit
(Kapa Biosystems, Roche, Basel, Switzerland) was used for the final quantification of the libraries.
2.5. Next-Generation Sequencing
The MiSeq System (MiSeq Reagent kit v3 2 × 300 cycles, Illumina, San Diego, CA, USA) was used
for sequencing. The libraries (final concentration of 4 nM, pooled by equal molarity) were denatured
by adding 0.2 nM NaOH and diluted to 40 pM with hybridization buffer from Illumina. The final
loading concentration was 14 pM libraries and 5% PhiX. Sequencing was conducted according to the
MiSeq instruction manual.
2.6. Data Analysis
Raw sequence data were analyzed with Archer analysis software (version 6.2.; Archer DX, Boulder,
CO, USA) for the presence of single-nucleotide variants (SNVs) as well as insertions and deletions
(indels) [17]. For the alignment, the human reference genome GRCh37 (equivalent UCSC version hg19)
was built. Molecular barcode (MBC) adapters were used to count unique molecules and characterize
sequencer noise, revealing mutations below standard NGS-based detection thresholds. The sequence
quality for each sample was assessed and the cutoff was set to 5% variant allele fraction. Total depth
of sequencing required 20.9 million reads. A reliable variant detection required a coverage of >250
reads. The limit of detection of this panel was 3 detected variants per 250 reads (the so-called alternate
observation). Large insertion/deletion (>50 bp) and complex structural changes could not be captured
by the method. The results were described using the latest version of Human Genome Variation
Society (HGVS) nomenclature for either the nucleotide or protein level (http://varnomen.hgvs.org/).
Individual gene variants were cross-checked in the Cosmic v90 database (Catalogue of Somatic
Mutations in Cancer, available online: http://cancer.sanger.ac.uk/cosmic, accessed on 5 September 2019)
for clinical relevance.
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3. Results
Out of the 262 total TC cases evaluated, 47 were included based on clinical history and morphology
consistent with autoimmune thyroiditis. Multiple tumor formation was demonstrated in 14 cases
(29.8%). The lymphocytic infiltrate of the non-neoplastic parenchyma was significant and presented with
slightly variable (medium to high) intensities in and around the coincidental tumors. The independent
carcinomatous foci were identified with variable sizes (2–23 mm) and frequently with different
histological and biological characteristics. Histopathological and biological features of all 14 matched
duplicate thyroid carcinomas are displayed in Table 1. Also, the histological subtype most frequently
fitting the criteria of classical papillary (cP, 13 samples) or papillary follicular variant (PF, 7 samples),
diffuse sclerotizing variant (5 samples), and oncocytic histological variant (3 samples) were diagnosed.
Discrepancies among the histological subtypes between parallel tumor foci could be identified in 6/14
cases. Coincidence was observed of cP and oncocytic variant in two cases, cP and diffuse sclerotizing
variant in three cases, and oncocytic and PF variant in one case. The cell proliferation rate determined
by the Mib1 IHC labeling index was generally low and did not differ significantly between matched
tumor foci. The IHC staining result for the mutant BRAF protein (VE1) was comparable in all but
one case. Simultaneous BRAF −/− samples were seen in 9/14 (64.3%), BRAF +/+ samples in 4/14
(28.6%) cases, while a discordant BRAF +/− pattern was demonstrated in 1/14 (7.1%) cases. The tumor
cell proliferation was generally low, with only <2% Mib-1 labeling in all of the evaluated samples,
irrespective of tumor stage, size, histological variant, and BRAF status. H-scores for nuclear p53
immunostaining proved to be variable but generally of weak/intermediate level (range of 0–160),
which was not consistent with a mutant-type p53 pattern (Table 1). The two independent foci of
simultaneous TC pairs from six cases were further sequenced using the VariantPlex 67-gene NGS panel
(Table 2).
The 12 DNA samples isolated from macrodissected FFPE tissue material corresponded to tumor
cell contents of over 70%, and all quantitative and qualitative requirements appeared optimal for
library preparation and sequencing.
The 67-gene panel data from the sequenced 12 TC tumor DNA resulted in a large number of exonic
nucleotide variants in highly variable amounts (13–111 SNVs/sample). The vast majority represented
missense variants associated with amino acid exchange (range of 7–65 variants/samples). Altogether,
41 pathogen gene variants were identified at the level of 5% variant allele frequencies (VAF) (0.05)
presenting with a highly variable rate and composition (Figure 1).
The involvement of the APC gene was observed most frequently (16 variants, also in multiple
fashions), followed by DDR2 (8 variants) and FBXW7 (6 variants). Both the distribution and the
allele frequency (VAF) of the variants detected within the individual TC tumors were highly different.
The number of coding gene variants ranged between 3 and 18 per sample, with the highest allele
frequency of 0.447 (JAK3 variant in case 5). BRAF pathogenic variants clearly validated the IHC
positivity obtained by the VE1 clone against the mutant protein in all three affected samples. TP53
variants were under-represented and generally present at only low frequencies (VAF range of 0.06–0.11).
The presence of TP53 variants was not associated with special phenotypic features and low allele
frequencies were consistent with the low/intermediate H-scores obtained following IHC using the
anti-p53 antibody DO-7.
Diagnostics 2020, 10, 48 5 of 11
Table 1. Multiple thyroid cancer (TC) tumor foci associated with Hashimoto’s thyroiditis (HT): histology
and functional parameters.
Case No. Sample Tumor Size(mm)
TNM
Class
Histology
Subtype
Grade of
Inflammation
MIB1
IHC (%)
BRAF
VE IHC
BRAF +/+
1 *
A 10 pT2 DS m <1% pos
B 6 pT2 cP m <1% pos
2
A 7 pT3 cP h <5% pos
B 5 pT3 cP h <5% pos
3
A 7 pT1b DS m <5% pos
B 5 pT1b cP m <5% pos
4
A 12 pT1b DS h <5% pos
B 2 pT1b cP h <5% pos
BRAF
−/−
5
A 5 pT1a cP m <1% neg
B 3 pT1a cP m <1% neg
6
A 4 pT1a O m <5% neg
B 6 pT1a cP m <5% neg
7
A 6 pT1a cP m <5% neg
B 3 pT1a cP m <5% neg
8 *
A 11 pT1a cP m <1% neg
B 12 pT1a O m <1% neg
9 *
A 10 pT1b PF h <1% neg
B 6 pT1b PF m <1% neg
10 *
A 11 pT1a DS h <1% neg
B 8 pT1a DS h <1% neg
11 *
A 13 pT1b PF h 1–2% neg
B 6 pT1b O h <1% neg
12
A 5 pT1a cP m <5% neg
B 4 pT1a cP m <5% neg
13
A 4 pT1a PF h <5% neg
B 2 pT1a PF h <5% neg
BRAF
+/− 14 *
A 23 pT3 PF m 1% pos
B 17 pT3 PF m <1% neg
Samples A and B represent two individual neoplastic foci within the same thyroid gland (TNM: tumor, nodes,
and metastases; histological subtypes: DS: diffuse sclerotic, cP: classical papillary, PF: papillary follicular variant,
O: oncocytic; grade of inflammation: h: high, m: medium; IHC: immunohistochemistry). * sample tested by
next-generation sequencing (NGS).
Table 2. Number of gene alterations detected and details of the identical variants in the matched TC
determined by a 67 multigene NGS panel. Samples A and B refer to tumors presented in Table 1. (AF:
allele frequency).
Case No. Sample Total no. ofVariants
No. of Identical
Variants
Identical
Gene
Type of Identical
Variants
AF of Identical
Variants (%)
1
A 12
1 BRAF p.Val600Glu (c.1799T>A)
23
B 9 9
8
A 18
0 - -
-
B 5 -
9
A 9
0 - -
-
B 15 -
10
A 11
0 - -
-
B 10 -
11
A 3
1 JAK3 p.Val722Ile (c.2164G>A)
30
B 7 44
14
A 13
0 - -
-
B 8 -
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Figure 1. The spectrum and frequency of pathogenic gene variants identified in synchronous thyroid 
carcinomas associated with Hashimoto’s thyroiditis. (APC: adenomatous polyposis coli; DDR2: 
discoidin domain receptor tyrosine kinase 2; FBXW7: F-box/WD repeat-containing protein 7; CDH1: 
cadherin 1; NOTCH1: Notch homolog 1, translocation associated; VHL: von Hippel-Lindau tumor 
suppressor; FOXL2: forkhead box protein L2; PTEN: phosphatase and tensin homolog; SMAD4: 
SMAD family member 4; STK11: serine/threonine kinase 11; BRAF: B-Raf proto-oncogene; FGFR1: 
Figure 1. The spectrum and frequency of pathogenic gene variants identified in synchronous thyroid
carcinomas associated with Hashimoto’s thyroiditis. (APC: adenomatous polyposis coli; DDR2:
discoidin domain receptor tyrosine kinase 2; FBXW7: F-box/WD repeat-containing protein 7; CDH1:
cadherin 1; NOTCH1: Notch homolog 1, translocation associated; VHL: von Hippel-Lindau tumor
suppressor; FOXL2: forkhead box protein L2; PTEN: phosphatase and tensin homolog; SMAD4: SMAD
family member 4; STK11: serine/threonine kinase 11; BRAF: B-Raf proto-oncogene; FGFR1: fibroblast
growth factor receptor 1; KDR: kinase insert domain receptor; H3F3A: H3.3 histone A; KRAS: Kirsten
Rat Sarcoma Viral Oncogene Homolog; NRAS: neuroblastoma RAS Viral Oncogene Homolog; PDGFRA:
platelet-derived growth factor receptor alpha; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha; TP53: tumor protein p53; ABL1: ABL proto-oncogene 1, nonreceptor tyrosine
kinase; AKT1: AKT serine/threonine kinase 1; CDKN2A: cyclin-dependent kinase inhibitor 2A; ERBB3:
erb-b2 receptor tyrosine kinase 3; FGFR3: fibroblast growth factor receptor 3; GNA11: G protein
subunit alpha 11; IDH2: isocitrate dehydrogenase 2; JAK3: Janus kinase 3; RHOA: Ras Homolog
Family Member A; SMO: Smoothened, Frizzled Class Receptor; ATM: Ataxia Telangiectasia Mutated;
CCNE1: Cyclin E1; CDK4: Cyclin-Dependent Kinase 4; EGFR: endothelial growth factor receptor; ESR1:
Estrogen Receptor 1; FGFR2: Fibroblast Growth Factor Receptor 2; GNAQ: G Protein Subunit Alpha Q;
GNAS: G Protein Subunit Alpha S; MET: Hepatocyte Growth Factor Receptor; MLH1: DNA Mismatch
Repair Protein Mlh1; PIK3R1: Phosphoinositide-3-Kinase Regulatory Subunit 1; RET: Proto-Oncogene
Tyrosine-Protein Kinase Receptor Ret).
Table 2 shows the data obtained after the comparison of coincident tumor foci within the same
thyroid gland. The number of the matching gene variants was surprisingly low. Only two out of
six cases presented with overlapping variant profiles, which were limited to a single event in both
cases. In case 1, we identified the same BRAF V600E mutation (BRAF: c.1799T>A, p.Val600Glu) in both
samples with VAF values of 0.235 and 0.097. The identical JAK3 variant (JAK3: c.2164G>A, p.Val722Ile)
could be demonstrated in case 5 at high frequencies (VAF of 0.30 and 0.44) in the parallel tumors. In the
remaining four out of six cases, no single gene variant overlapped within the simultaneous tumor
genomes despite the relatively large series of positive events, including characteristic driver mutations
(e.g., VHL, KRAS, PIK3CA, PTEN, and TP53). Interestingly, the allele frequencies of these individual
gene variants were highly variable, and the majority of them presented with relatively low frequencies,
suggesting a potential subclonal, passenger nature (Figure 2).
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4. Discussion
NGS is a unique tool that can demonstrate the complex mutational profile in malignancies from
clinical samples and also enables the analysis of DNA from archived FFPE tumor tissues, provided that
the tissue sample is representative and the quality of the isolated genomic DNA is preserved [18,19].
Both diagnostic and predictive indications have been increasingly reported, and NGS-based thyroid
cancer testing has become generally available. Gene panel sequencing has recently been considered to
differentiate thyroid nodules with indeterminate cytological findings, which may support decisions for
surgery [16,20]. On the other hand, NGS was found to be highly effective at defining targetable molecular
pathways in advanced as well as poorly differentiated/anaplastic thyroid carcinomas [10,12,14,21].
Moreover, multigene DNA sequencing was reported to be useful for differentiating PTC developing
as part of familial cancer syndromes at young ages, as was presented, for example, for familial
adenomatous polyposis (FAP) syndrome [22].
In addition to what was previously mentioned, NGS-based gene panel testing enables the
performance of comparative studies and highlights the potential clonal relation of simultaneously
occurring malignancies. This is particularly relevant for multiple independent tumors developing in
the same organ suggesting some principal common pathobiology. To date, multiple neoplasias of the
thyroid were only compared at a single-case level by detailed mutational testing, according to our
knowledge [23,24].
In the current study, 14 TC cases were selected for multifocality and unambiguous HT
etiology. The individual tumors presented with significant diversity regarding histological subtype,
immunophenotype, and BRAF status, at least to some extent. However, features potentially associated
with the HT etiology were not obvious. We assume that the described high pathomorphological
variability is the result of complex processes determined by individual genetic/epigenetic changes.
To obtain greater insight into these features, NGS sequencing data of six available cases with double
malignancies were processed and compared.
The VariantPlex solid tumor NGS panel used in our study simultaneously detected and
characterized SNVs and indels in 67 genes commonly associated with solid tumor progression.
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On the other hand, this panel was not designed to detect large sequential alterations and structural
rearrangements of the genome. This restriction should be considered, especially as chromosomal
translocations (e.g., RET/PTC) appear to be clinically significant in thyroid tumors, primarily in
the classical papillary variant [25]. In the present study, however, we were principally interested
in SNVs in HT-related carcinoma and, further, in the potential clonal correlations characteristic of
multifocality. Using the VariantPlex panel, we identified pathogenic variants of 41 genes in total, which
were described in association with cancer according to the Cosmic database. Several genes harbored
multiple variants. Interestingly, the involvement of the APC gene was the most frequent in our cohort
of 12 TCs associated with HT. However, comparison of the exact SNV sites of the simultaneous nodules
did not reveal any exact match of the detected APC alterations. Therefore, the individual changes
were interpreted as tumor-related somatic variants, and the germline involvement of the APC gene in
the evaluated patients could be excluded. Further frequent variants affected DDR2, FBXW7, CDH1,
NOTCH1, and VHL genes. Interestingly, the dedicated members of the classical MAPK pathway
(EGFR1, KRAS, NRAS, BRAF, RET, etc.) were generally under-represented. Due to the high number
and the distinct distribution of variants, the mutational changes of the HT-related TCs generally
appeared to deviate from the gene involvement described for classical papillary TCs [26,27].
The comparison of coincidental tumors from the same thyroid gland resulted in highly divergent
genetic profiles in the individual TCs. Common gene variants could be demonstrated in only two out
of the six evaluated cases, each presenting with a single gene variant occurring in both tumor foci
(BRAF and JAK3). However, each tumor pair featured several additional dominant variants which
were unrelated. The specific JAK3 variant c.2164G>A (p.Val722Ile) identified in case 11 is unique and,
thus, would suggest a common origin of the two neoplastic foci. As such, this would be the only
sign of an early genetic hit, while additional changes indicate independent tumor development and
do not support the potential of intraorgan metastatic spread. On the other hand, BRAF c.1799T>A
(p.Val600Glu, referred to as V600E in the literature) kinase domain mutations are frequent enough
in TC to occur incidentally in both coexisting foci, as we found in case 1. The value of the BRAF
V600E variant as a clonality marker is therefore questionable in this particular case. Apart from these
exceptions, we could not provide any further trace of genetic relationship between independent foci
from the same thyroid gland.
Our result on multiple TCs associated with HT is based on low case numbers and should be
considered as preliminary. Previous findings on multifocal carcinogenesis are rare but all support the
idea of independent clonal evolution of simultaneous tumors within the same thyroid tissue. Whole
exome and transcriptome sequencing provided evidence that coincidental adenomatoid nodules and
a PTC from the same surgical sample had no overlapping mutations [23]. Similar conclusions were
made in the report on a case with simultaneous independent papillary and medullary carcinomas [24].
Moreover, distinct morphological components of a composite thyroid carcinoma also had highly
different mutational profiles, indicating divergent growth and no clonal association despite the close
spatial relationship [28].
According to earlier data, multifocality is a hallmark of radiation-related TCs, which are
characterized by genetic diversity and inconsistent gene variant patterns [29,30]. Similar to radiotoxic
injury, thyroid follicular cells are exposed to continuous and direct cellular irritation as a consequence
of autoimmune inflammation. Oxidative stress and peroxidation are suggested to be major factors in
thyroid carcinogenesis, as the deregulation of H2O2-dependent thyroid hormone synthesis in damaged
follicular epithelial cells contributes to massive DNA damage [31,32]. In line with this, a clear increase
in thyroperoxidase expression and function as well as the reduction of the neutralizing GSH activity in
association with manifest HT in the thyroid parenchyma was reported [33]. As such, an immune attack
associated with oxidative stress may be a key mechanism causing enhanced random DNA damage
throughout the organ in HT, resulting in multiple transformation foci characterized by numerous and
highly variable mutations.
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Current data suggest characteristic genetic patterns for different thyroid carcinoma etiologies.
Sporadic, classical forms appear to be associated with isolated defects of the MAPK pathway and
frequent BRAF mutations. Early onset multifocal PTC may carry the APC gene mutation and, as
such, falls under the familial cancer syndrome FAP. Radiation-related TC differs from the sporadic
forms escaping the classical molecular pathways and presenting with highly variable mutational
profiles. Similar to this, we now provide data indicating the high genetic diversity and a multiclonal
tumorigenesis in relation with clinically significant autoimmune thyroid disease. As demonstrated by
our comparative NGS studies, the genetic diversity may also lead to discrepancies of clinically relevant
mutations (e.g., BRAF and NRAS). Multiple lesions with different mutational profiles define a new
challenge for therapeutic decision-making and long-term follow-up of patients with thyroid cancer.
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G.M.: writing, supervision. All authors have read and agreed to the published version of the manuscript.
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